Specify a stock or a cryptocurrency in the search bar to get a summary
Caribou Biosciences Inc
CRBUCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Address: 2929 7th Street, Berkeley, CA, United States, 94710
Analytics
WallStreet Target Price
15.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CRBU
Dividend Analytics CRBU
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CRBU
Stock Valuation CRBU
Financials CRBU
Results | 2019 | Dynamics |